PanKind, The Australian Pancreatic Cancer Foundation[Grants and Funding] - Search Results

Year	Number of Results
2021	2
2023	5
2024	2
2025	0

1

Antibody drug conjugates: hitting the mark in pancreatic cancer?

Wittwer NL, Brown MP, Liapis V, Staudacher AH. Wittwer NL, et al. J Exp Clin Cancer Res. 2023 Oct 25;42(1):280. doi: 10.1186/s13046-023-02868-x. J Exp Clin Cancer Res. 2023. PMID: 37880707 Free PMC article. Review.

2

Bile Acids and Microbiota Interplay in Pancreatic Cancer.

Malhotra P, Palanisamy R, Caparros-Martin JA, Falasca M. Malhotra P, et al. Cancers (Basel). 2023 Jul 11;15(14):3573. doi: 10.3390/cancers15143573. Cancers (Basel). 2023. PMID: 37509236 Free PMC article. Review.

3

Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.

Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, Sahni S. Byeon S, et al. Int J Cancer. 2024 Jul 15;155(2):365-371. doi: 10.1002/ijc.34928. Epub 2024 Mar 22. Int J Cancer. 2024. PMID: 38519999

4

Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance.

Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Murphy KJ, et al. Cancers (Basel). 2021 Jul 12;13(14):3481. doi: 10.3390/cancers13143481. Cancers (Basel). 2021. PMID: 34298706 Free PMC article. Review.

5

Global Perceptions on ERAS^® in Pancreatoduodenectomy.

Karunakaran M, Roulin D, Ullah S, Shrikhande SV, De Boer HD, Demartines N, Barreto SG. Karunakaran M, et al. World J Surg. 2023 Dec;47(12):2977-2989. doi: 10.1007/s00268-023-07198-9. Epub 2023 Oct 3. World J Surg. 2023. PMID: 37787776 Free PMC article.

6

Development of [²²⁵Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration.

Hull A, Hsieh W, Borysenko A, Tieu W, Bartholomeusz D, Bezak E. Hull A, et al. EJNMMI Radiopharm Chem. 2023 Sep 7;8(1):22. doi: 10.1186/s41181-023-00209-z. EJNMMI Radiopharm Chem. 2023. PMID: 37679594 Free PMC article.

7

In vitro characterisation of [¹⁷⁷Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer.

Hull A, Hsieh W, Tieu W, Bartholomeusz D, Li Y, Bezak E. Hull A, et al. EJNMMI Radiopharm Chem. 2023 Aug 14;8(1):18. doi: 10.1186/s41181-023-00204-4. EJNMMI Radiopharm Chem. 2023. PMID: 37578571 Free PMC article.

8

Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients.

Gillson JE, Byeon S, Chou A, Maloney S, Pavlakis N, Clarke SJ, Chan DL, Diakos CI, Gill AJ, Samra JS, Mittal A, Sahni S. Gillson JE, et al. Eur J Clin Invest. 2024 Nov 2:e14341. doi: 10.1111/eci.14341. Online ahead of print. Eur J Clin Invest. 2024. PMID: 39487743

9

HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer.

Pang TCY, Xu Z, Mekapogu AR, Pothula S, Becker T, Corley S, Wilkins MR, Goldstein D, Pirola R, Wilson J, Apte M. Pang TCY, et al. Cancers (Basel). 2021 Jun 2;13(11):2763. doi: 10.3390/cancers13112763. Cancers (Basel). 2021. PMID: 34199452 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year